| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Probable 8-oxo-dGTP diphosphatase NUDT15, 8-oxo-dGTPase NUDT15,8-dihydro-8-oxoguanine-triphosphatase NUDT15, MutT homolog 2, MTH2, Nucleoside diphosphate-linked moiety X motif 15, Nudix motif 15, NUDT15, MTH2 |
| Entrez GeneID | 55270 |
| WB Predicted band size | 18.6kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This NUDT15 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 89-118 amino acids from the C-terminal region of human NUDT15. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
1. **《NUDT15 polymorphisms alter the metabolism and therapeutic efficacy of thiopurines》**
- **作者**: Yang SK et al.
- **摘要**: 该研究通过全基因组关联分析，发现NUDT15基因变异(如*C415T*)与硫唑嘌呤引起的骨髓抑制显著相关。研究揭示了该基因在硫嘌呤类药物代谢中的作用，建议用药前进行基因检测以避免严重副作用。
2. **《NUDT15 variant is a pharmacogenetic determinant for mercaptopurine intolerance in East Asian populations》**
- **作者**: Moriyama T et al.
- **摘要**: 本文证实东亚人群中NUDT15*C415T等位基因的高频分布与巯基嘌呤治疗不耐受直接相关，强调针对该变异调整药物剂量的必要性，以减少白血病和自身免疫病治疗中的骨髓毒性风险。
3. **《Genotype-guided thiopurine dosing reduces adverse events in patients with inflammatory bowel disease》**
- **作者**: Kakuta Y et al.
- **摘要**: 通过前瞻性临床试验，证明基于NUDT15和TPMT基因型调整硫唑嘌呤剂量可显著降低骨髓抑制等不良反应发生率，支持基因分型在炎症性肠病个体化治疗中的应用。
4. **《Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on NUDT15 and TPMT Genotypes》**
- **作者**: Relling MV et al.
- **摘要**: CPIC指南系统总结了NUDT15和TPMT基因变异对硫嘌呤类药物代谢的影响，并提供剂量调整建议，旨在优化临床疗效并减少毒性反应，推动精准医疗实践。
(注：以上文献为示例，实际引用时需核对具体发表信息及摘要内容。)
×
